
FISEVIER

Contents lists available at ScienceDirect

J Clin Tuberc Other Mycobact Dis

journal homepage: www.elsevier.com/locate/jctube



Letter to editor

Bacillus Calmette-Guerin (BCG) vaccine in Iran



ARTICLE INFO

Keywords: Tuberculosis Bacillus Calmette-Guerin

Tuberculosis (TB) has been reported as one of the leading causes of death among infectious diseases by World Health Organization (WHO) in the last two decades, especially in developing countries [1]. In Iran, despite the existence of effective control programs, TB continues to be a major challenge with an estimated 10,000 notified cases in 2016 [1]. Vaccination with the Bacillus Calmette-Guerin (BCG) is among the most important TB control strategies in Iran [2]. According to Iranian neonatal vaccination policy, BCG has been given as a single dose at children aged <6 years, shortly after birth or at first contact with the health services [3]. Despite advantages of BCG vaccine, local and systemic adverse reactions have been reported by several authors in the world [4-8]. Two most severe of these are lymphadenitis and disseminated BCG infection [4]. Despite the fact that adverse reactions after BCG vaccination are well described, studies report very different rates. This could be due to different vaccination procedures and BCG vaccine strains [2,9]. There are a number of distinct BCG vaccines in the world, including six that are currently in use: Pasteur 1173 P2, the Danish 1331, the Glaxo 1077, the Tokyo 172-1, the Russian BCG-I, and the Moreau RDJ strains [10]. According to WHO data sheet, the Pasteur 1173 P2 is known to induce more adverse reactions than the other strains [10].

We have recently indicated that all of the BCG vaccine strains in Iran were BCG-Pasteur 1173p2 strain and no genetic diversity among stocks and ready-for-use vaccine vials were detected [2].

As Iran lacks a post-vaccination surveillance system, available information regarding BCG adverse reactions in Iran is limited by the lack of microbiological confirmation [3]. However, based on local studies in Iran, lymphadenitis was the most common adverse effect of BCG vaccination in infants. Likewise, in our previous study, we confirmed the presence of infection due to *Mycobacterium bovis* BCG strain Pasteur in all investigated patients aged <6 years with lymphadenitis [4].

Other factors may also cause complications after BCG vaccination, including dose of the vaccine, intradermal inoculation of BCG vaccine and age at vaccination [10].

In conclusion, although, BCG vaccination is among the effective tools for control of TB, however, as long as Iran uses the Pasteur BCG strain which is generally more reactogenic than other available strains, it is difficult to avoid the possibility of such adverse reactions as seen in our previous study. Establishing a post-vaccination surveillance system as well as a regular quality and quantity analysis of BCG vaccines are strongly recommended.

References

- [1] Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017;49(3):1602308.
- [2] Fallah F, Karimi A, Abdolghafoorian H, Mohammadzadeh A, Zahraei S, Goudarzi H, et al. Molecular analysis of the bacille Calmette-Guérin vaccine strain currently being used in Iran. Int J Tuberculosis Lung Dis 2016;20(2):223–7.
- [3] Shojaei H, Rahimi-Hajiabadi H, Heidarieh P, Hashemi-Shahraki A, Emadoleslami M, Ataei B, et al. Molecular microbiological investigation of post-vaccination bacille Calmette-Guérin infection in Iranian patients. Int J Tuberculosis Lung Dis 2011;15(11):1497–504.
- [4] Shahi F, Fallah F, Goudarzi H, Baniasad M, Pourabbas B, Mohammadzade A, et al. Molecular characterization of mycobacterium strains isolated from children with BCG induced lymphadenitis. Res Med 2015;39(1):30–5.
- [5] Deeks SL, Clark M, Scheifele DW, Law BJ, Dawar M, Ahmadipour N, et al. Serious adverse events associated with bacille Calmette-Guerin vaccine in Canada. Pediatr Infect Dis J 2005;24(6):538–41.
- [6] Satti I, Meyer J, Harris SA, Thomas Z-RM, Griffiths K, Antrobus RD, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis 2014:14(10):939–46.
- [7] Fallah F, Chavoshzade Z, Karimi A, Moein M, Poorpak Z, Sajadinia R. 473 Determining the correlation between the scar size of Bcg and suffering from asthma in children, by assessing the level of thelper1/thelper2. Arch Dis Child 2012:97(Suppl 2), A138-A9.
- [8] Fallah F, Eslami G, Pourbaba R, Goudarzi H, Taheri S, Marhamati N. 1839 The role of CFU of BCG vaccine in tuberculin skin reaction. Arch Dis Child 2012;97(Suppl 2). A520-A.
- [9] Anderson EJ, Webb EL, Mawa PA, Kizza M, Lyadda N, Nampijja M, et al. The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine 2012;30(12):2083–9.
- [10] World Health Organization (WHO). Information sheet-observed rate of vaccine reactions Bacille Calmette-Guérin (BCG) vaccine; 2012.

Fatemeh Fallah¹, Mohammad Javad Nasiri¹, Ali Pormohammad*
Department of Microbiology, School of Medicine, Shahid Beheshti University
of Medical Sciences, Tehran, Iran
E-mail address: alipormohammad@sbmu.ac.ir

^{*} Corresponding author.

The first authors.